| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
PF9601N targets monoamine oxidase B (MAO-B), an enzyme that catalyzes the oxidative deamination of biogenic and xenobiotic amines. Inhibition of MAO-B increases dopamine levels in the brain and provides neuroprotection in Parkinson's disease models.
|
|---|---|
| ln Vitro |
In vitro, PF9601N selectively inhibits MAO-B with high potency. It has neuroprotective properties in cell models of Parkinson's disease. It prevents MPTP-induced reductions in dopamine levels in the striatum.
|
| ln Vivo |
In vivo, PF9601N prevents MPTP-induced dopamine depletion in the striatum of mice at doses ranging from 29.5 to 8.47 µmol/kg. It exhibits neuroprotective effects in several in vivo models of Parkinson's disease. These findings support its potential for treating neurodegenerative diseases.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for PF9601N involves measuring MAO-B activity using a substrate such as kynuramine or benzylamine. The enzyme is incubated with the compound, and the production of the oxidative product is monitored fluorometrically or spectrophotometrically. The IC50 or ID50 is determined.
|
| Cell Assay |
Cellular assays for PF9601N involve treating neuronal cell cultures with the compound and assessing its neuroprotective effects against neurotoxins such as MPTP or 6-hydroxydopamine. Cell viability, oxidative stress markers, and dopamine levels are measured to evaluate neuroprotection.
|
| Animal Protocol |
In vivo efficacy of PF9601N is evaluated in mouse models of Parkinson's disease, particularly the MPTP-induced model. Mice are treated with PF9601N prior to or concurrently with MPTP administration. Dopamine levels in the striatum are measured by HPLC to assess the neuroprotective effect.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of PF9601N have not been extensively characterized. It has a molecular weight of 290.36 g/mol and a molecular formula of C19H18N2O. Its ability to cross the blood-brain barrier is implied by its in vivo efficacy in the brain.
|
| Toxicity/Toxicokinetics |
Toxicity data for PF9601N are limited. As a research-grade compound, comprehensive toxicological evaluations have not been published.
|
| References | |
| Additional Infomation |
PF9601N is a research compound for studying MAO-B inhibition and neuroprotection in Parkinson's disease. It has not entered clinical trials. Its mechanism involves selective inhibition of MAO-B and neuroprotection against excitotoxicity.
|
| Molecular Formula |
C19H18N2O
|
|---|---|
| Molecular Weight |
290.359
|
| Exact Mass |
290.142
|
| Elemental Analysis |
C, 78.59; H, 6.25; N, 9.65; O, 5.51
|
| CAS # |
133845-63-3
|
| PubChem CID |
9947954
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.86
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
22
|
| Complexity |
382
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(COC2=CC=C3C(C=C(CNCC#C)N3)=C2)=CC=CC=C1
|
| InChi Key |
YFPNAYXYKXAKJC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18N2O/c1-2-10-20-13-17-11-16-12-18(8-9-19(16)21-17)22-14-15-6-4-3-5-7-15/h1,3-9,11-12,20-21H,10,13-14H2
|
| Chemical Name |
N-[(5-phenylmethoxy-1H-indol-2-yl)methyl]prop-2-yn-1-amine
|
| Synonyms |
PF9601N
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~430.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4440 mL | 17.2200 mL | 34.4400 mL | |
| 5 mM | 0.6888 mL | 3.4440 mL | 6.8880 mL | |
| 10 mM | 0.3444 mL | 1.7220 mL | 3.4440 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
